Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-01-11
2005-01-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S141100, C424S143100, C424S144100
Reexamination Certificate
active
06841152
ABSTRACT:
Methods are provided for preventing the development of autoimmune diseases in susceptible subjects and for prolonging acceptance of tissue transplants by administration of an agonist of the T cell CD28 co-stimulatory receptor.
REFERENCES:
patent: WO9005541 (1990-05-01), None
patent: WO9200092 (1992-01-01), None
patent: WO9319767 (1993-10-01), None
patent: WO9428912 (1994-12-01), None
patent: WO9503408 (1995-02-01), None
patent: WO9505464 (1995-02-01), None
patent: WO9614865 (1996-05-01), None
Liang et al., J. Immunol. 1999; 163:2322-2329.*
Bowman et al. Immunology Today 15(3):115-120 1994.*
Shehadeh et al., “Effect of Adjuvant Therapy on Development of Diabetes in Mouse and Man,” Lancet, 334:706-707 (1994).
Dahlquist et al., “The Cumulative Incidence of Childhood Diabetes Mellitus in Sweden Unaffected By BCG-Vaccination,” Diabetologia, 38:873-874 (1995).
Sperling et al., “CD34 is A Murine T Cell Costimulatory Receptor That Functions Indepdently Of CD28,” J. Exp. Med., 182:139-146 (1995).
Grewal et al., “Requirement For CD40 Ligand In Costimulation Induction, T Cell Activation, and Experimental Allergic Encephalomyelitis,” Science, 273:1864-1867 (1996).
Wingren et al., “T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles,” Critical Reviews In Immunology, 15(3&4):235-253 (1995).
Ekerfelt et al., “Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis,” Clin. Exp. Immunol 123:112-118 (2001).
Karandikar et al. “Tissue-Specific Up-Regulation of B7-1 Expression and Function During the Course of Murine Relapsing Experimental Autoimmune Encephalomyelitis,” The Journal of Immunology 161:192-199 (1998).
Saoudi et al. “TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependant autoimmune disease,” Eur. J. Immunol. 23:3096-3103 (1993).
Weintraub et al. “Up-Regulation and the Costimulatory Molecules B7-1 and B7-2 on Peripheral Lymphocytes in Autoimmune B6/gld Mice,” The Journal of Immunology 159:4117-4126 (1997).
Yu et al. “Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives is Associated with Eligibility for the Diabetes Prevention Trial-Type 1,” Diabetes 50:1735-1740 (2001).
Arreaza et al., “Interleukin-4 Potential Immunoregulatory Agent in Therapy of Insulin-Dependent Diabetes Mellitus,”Clin. Immunother.(4):251-260 (Oct. 1996).
Bendelac et al., “Syngeneic Transfer of Autoimmune Diabetes from Diabetic Nod Mice to Healthy Neonates,”J. Exp. Med.(166):823-832 (Oct. 1987).
Berman et al., “Decreased IL-4 Production in New Onset Type I Insulin-Dependent Diabetes Mellitus1,”J. Immunol.(157):4691-4696 (1996).
Bluestone, J.A., “New Perspectives of CD28-B7-Mediated T Cell Costimulation,”Immunity(2):555-559 (Jun. 1995).
Cameron M.J. et al.: “Cytokline-and costimulation-mediated therapy of IDDM”Critical Reviews In Immunology17(5-6):537-544 (1997).
Christianson et al., “Adoptive Transfer of Diabetes Into Immunodeficient NOD-scid/scid Mice,”Diabetes(42):44-55 (Jan. 1993).
Corry et al., “Differential Effects of Blockade of CD28-B7 on the Development of Th1 or Th2 Effector Cells in Experimental Leishmaniasis1, ”J. Immunol.(153):4142-4148 (1994).
Freeman et al., “B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1 Preferentially Costimulates the Initial Production of IL-4,”Immunity(2):523-532 (May 1995).
Freeman et al., “Murine B7-2, an Alternative CTLA4 Counter-Receptor that Costimulates T Cell Proliferation and Interleukin 2 Production,”J. Exp. Med.(178):2185-2192 (Dec. 1993).
Haskins and McDuffie, “Acceleration of Diabetes in Young NOD Mice With a CD4+Islet-Specific T Cell Clone,”Science(249):1433-1436 (Sep. 1990).
Jaramillo et al., “Insulin Dependent Diabetes Mellitus in the Non-Obese Diabetic Mouse: A Disease Mediated by T Cell Anergy?,”Life Sciences(55):1163-1177 (Aug. 1994).
Jenkins et al., “Induction and Maintenance of Anergy in Mature T Cells,”Adv. Exp. Med. Biol.(292):167-176 (1991).
Kalinski et al., “Functional Maturation of Human Naïve T Helper Cells in the Absence of Accessory Cells”J. Immunol.(154):3753-3760 (1995).
Katz et al., “T Helper Cell Subsets in Insulin-Dependent Diabetes,”Science(268):1185-1188 (May, 1995).
Kawamura et al., “Comparative Analysis of B7-1 and B7-2 Expression in Langerhans Cells: Differential Regulation by T Helper Type 1 and T Helper Type 2 Cytokines,”Eur. J. Immunol(25):1913-1917 (1995).
King et al., “CD28 Activation Promotes Th2 Subset Differentiation by Human CD4+,”Eur. J. Immunol.(25):587-595 (1995).
Kuchroo et al., “B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy,”Cell(80):707-718 (Mar., 1995).
Lenschow D.J. et al: “DC28/B7 Regulation of Th1 and Th2 Subsets in the Development of Autoimmune Diabetes”Immunity5(3):285-293 (1996).
Lenschow et al., “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse,”J. Exp. Med.(181):1145-1155 (Mar. 1995).
Lenschow et al., “Expression and Functional Significance of an Additional Ligand for CTLA-4,”Proc. Natl. Acad. Sci. USA(90):11054-11058 (Dec. 1993).
Liblau et al., “Th1 and Th2 CD4+ T Cells in the Pathogenesis of Organ-Specific Autoimmune Dieases”Immunology Today(16):34-38 (1995).
Linsley et al., “T-Cell Antingen CD28 Mediates Adhesion With B Cells By Interacting With Activation Antigen B7/BB-1,”Proc. Natl. Acad. Sci USA(87):5031-5035 (Jul. 1990).
Lu et al., “CTLA-4 Ligands Are Required to Induce an In Vivo Interleukin 4 Response to a Gastointestinal Nematode Parasite,”J. Exp. Med.(180):693-698 (Aug. 1994).
Mueller et al., “Pancreatic Expression of Interleukin-4 Abrogates Insulitis and Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice,”J. Exp. Med.(184):1093-1099 (Sep. 1996).
Niklinska et al., “CD45 Tyrosine Phosphatase Activity and Membrane Anchoring Are Required for T-Cell Antigen Receptor Signaling,”Mol.Cell.Biol.,(14):8078-8084 (1994).
Peach et al., “Complementarity Determining Region 1 (CDR1)-and CDR3-Analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1,”J. Exp. Med.(180):2049-2058 (Dec. 1994).
Rabinovitch, “Immunoregulatory and Cytokine Imbalances in the Pathogenesis of IDDM,”Diabetes(43):613-621 (May 1994).
Rapoport et al., “Interleukin 4 Reverses T Cell Proliferative Unresponsiveness and Prevents the Onset of Diabetes in Nonobese Diabetic Mice,”J. Exp. Med.(178):87-99 (Jul. 1993).
Rohane et al., “Islet-Infiltrating Lymphocytes from Prediabetic NOD Mice Rapidly Transfer Diabetes to NOD-scid/scid Mice,”Diabetes(44):550-554 (May 1995).
Seder et al., “CD28-Mediated Costimulation of Interleukin 2 (IL-2) Production Plays a Critical Role in T-Cell Priming for IL-4 and Interferon γ Production,”J. Exp. Med.(179):299-304 (Jan. 1994).
Serreze et al., “Defects in the Differentiation and Function of Antigen Presenting Cells in NOD/Lt Mice1,”J. Immunol.(150):2534-2540 (1993).
Shehadeh et al., “Altered Cytokline Activity in Adjuvant Inhibition of Autoimmune Diabetes,”J. Autoimmun.(6):291-300 (1993).
Stack et al., “IL-4 Treatment of Small Splenic B Cells Induces Costimulatory Molecules B7-1 and B7-21,”J. Immunol.(152):5723-5733 (1994).
Thompson, “Distinct Roles for the Costimulatory Ligands B7-1 and B7-2 in T Helper Cell Differentiation,”Cell(81):979-982 (Jun., 1995).
Wang et al., “The Role of CD4+ and CD8+ T Cells
Gambel Phillip
Ouspenski Ilia
The Wellesley Hosp. Foundation
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for protecting against autoimmune diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for protecting against autoimmune diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for protecting against autoimmune diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3366506